Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects

Immune-priming of the Tumor Microenvironment by Radiotherapy

(2015) Vafa Shahabi et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

(2015) X. Liu et al.   CANCER RESEARCH

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity

(2015) H. G. Caruso et al.   CANCER RESEARCH

The Evolution of T-cell Therapies for Solid Malignancies

(2015) K. Fousek et al.   CLINICAL CANCER RESEARCH

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases

(2015) S. C. Katz et al.   CLINICAL CANCER RESEARCH

Targeting cancer-specific mutations by T cell receptor gene therapy

(2015) Thomas Blankenstein et al.   CURRENT OPINION IN IMMUNOLOGY

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

(2015) Nabil Ahmed et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Engineering CAR-T cells: Design concepts

(2015) Shivani Srivastava et al.   TRENDS IN IMMUNOLOGY

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators

(2015) Isabelle Le Mercier et al.   Frontiers in Immunology

CAR T Cells for Solid Tumors

(2014) Sunitha Kakarla et al.   CANCER JOURNAL

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cell Receptor-Engineered T Cells to Treat Solid Tumors: T Cell Processing Toward Optimal T Cell Fitness

(2014) Cor H.J. Lamers et al.   Human Gene Therapy Methods

Personal neoantigen cancer vaccines

(2014) Edward F Fritsch et al.   OncoImmunology

Chemotherapy Acts as an Adjuvant to Convert the Tumor Microenvironment into a Highly Permissive State for Vaccination-Induced Antitumor Immunity

(2013) T. H. Kang et al.   CANCER RESEARCH

Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia

(2013) Eric Tran et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells

(2013) Petra C Schuberth et al.   Journal of Translational Medicine

Arming Cytokine-induced Killer Cells With Chimeric Antigen Receptors: CD28 Outperforms Combined CD28–OX40 “Super-stimulation”

(2013) Andreas A Hombach et al.   MOLECULAR THERAPY

Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma

(2013) Sunitha Kakarla et al.   MOLECULAR THERAPY

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

(2013) Cor HJ Lamers et al.   MOLECULAR THERAPY

Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma

(2013) Lihua E. Budde et al.   PLoS One

PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

(2013) V. D. Fedorov et al.   Science Translational Medicine

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

(2013) G. L. Beatty et al.   Cancer Immunology Research

Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity

(2013) L.-C. S. Wang et al.   Cancer Immunology Research

T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

(2013) M. V. Maus et al.   Cancer Immunology Research

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

(2013) Zakaria Grada et al.   Molecular Therapy-Nucleic Acids

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells

(2012) Sepideh Khaleghi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects

(2012) Maria Grazia Ruocco et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group

(2012) David Ebb et al.   JOURNAL OF CLINICAL ONCOLOGY

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

(2012) Christopher C Kloss et al.   NATURE BIOTECHNOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natural Innate and Adaptive Immunity to Cancer

(2011) Matthew D. Vesely et al.   Annual Review of Immunology

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes

(2011) Fangfang Liu et al.   BREAST CANCER RESEARCH AND TREATMENT

Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion

(2011) Yuan Zhang et al.   CANCER LETTERS

The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity

(2011) B. C. Burnette et al.   CANCER RESEARCH

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells

(2010) C. H. J. Lamers et al.   BLOOD

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor

(2010) B. Jena et al.   BLOOD

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergistic Antitumor Effects of Regulatory T Cell Blockade Combined with Pemetrexed in Murine Malignant Mesothelioma

(2010) M. Anraku et al.   JOURNAL OF IMMUNOLOGY

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

(2010) V Hoyos et al.   LEUKEMIA

TCR gene-engineered T cell: Limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity

(2010) Nadine Pouw et al.   MOLECULAR IMMUNOLOGY

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment

(2009) Y. Lee et al.   BLOOD

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model

(2009) A. Di Stasi et al.   BLOOD

The Antitumor Effects of CIK Cells Combined with Docetaxel Against Drug-Resistant Lung Adenocarcinoma Cell Line SPC-A1/DTX in Vitro and in Vivo

(2009) Pengying Liu et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN

(2009) Zvi G. Fridlender et al.   CANCER CELL

The promise and potential pitfalls of chimeric antigen receptors

(2009) Michel Sadelain et al.   CURRENT OPINION IN IMMUNOLOGY

Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice

(2009) Angélica M. Santos et al.   JOURNAL OF CLINICAL INVESTIGATION

A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity

(2009) Y. Zhao et al.   JOURNAL OF IMMUNOLOGY

Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression

(2009) Nabil Ahmed et al.   MOLECULAR THERAPY

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY

Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication

(2009) Xiao-Song Zhong et al.   MOLECULAR THERAPY

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

(2009) C. Carpenito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity

(2009) C. S. Hinrichs et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Selective accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human bone marrow

(2008) U. Palendira et al.   BLOOD

IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes

(2008) S. Kaneko et al.   BLOOD

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy

(2008) C. S. Hinrichs et al.   BLOOD

Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement

(2008) C. T. Garnett et al.   CLINICAL CANCER RESEARCH

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE